Russia's Bowel Cancer Drug Market Set for 3pc Annual Growth

Decision Resources predicts that Russia's colorectal cancer drug market will grow by three per cent a year to reach $487m in 2016.

The Russian market for colorectal (bowel) cancer drugs is likely to grow by three per cent annually until 2016, a report has predicted.

Research and advisory firm Decision Resources says that the market will grow to approximately $487 million, with a number of factors contributing to the increase.

These include a rise in the number of patients with bowel cancer and the launches of four new branded therapies - Regeneron and Sanofi's Zaltrap; Bayer's regorafenib, Alchemia's HA-irinotecan; and ImClone Systems and Eli Lilly's ramucirumab.

The report also suggests that changes in medical practice will have an impact on the market, in particular an improvement in access to testing for KRAS mutations.